` RAD (Radiopharm Theranostics Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

RAD
vs
S&P/ASX 300

Over the past 12 months, RAD has underperformed S&P/ASX 300, delivering a return of -29% compared to the S&P/ASX 300's 10% growth.

Stocks Performance
RAD vs S&P/ASX 300

Loading
RAD
S&P/ASX 300
Add Stock

Performance Gap
RAD vs S&P/ASX 300

Loading

Over the past 12 months, RAD has underperformed S&P/ASX 300 by 39.3%.

RAD
S&P/ASX 300
Difference
www.alphaspread.com

Performance By Year
RAD vs S&P/ASX 300

Loading
RAD
S&P/ASX 300
Add Stock

Competitors Performance
Radiopharm Theranostics Ltd vs Peers

S&P/ASX 300
RAD
ABBV
AMGN
GILD
VRTX
Add Stock

Radiopharm Theranostics Ltd
Glance View

Market Cap
52.8m AUD
Industry
Biotechnology

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2021-11-25. The firm is a developer of platform of radiopharmaceutical products for both diagnostic and therapeutic uses. The company has a pipeline of four licensed platform technologies, namely Nano- monoclonal antibodies (mAbs) technology, Pivalate, AVb6 Integrin and PSA-mAb. Nano-mAbs technology platform provides Nano-mAbs, which are made using genetically engineered camelid derived single domain antibodies (sdAb), that are labelled with radioisotopes to diagnose and treat specific cancers expressing HER-2, TROP-2, PD-L1 and PTK7 receptors. Pivalate is an F-FPIA radiotracer, and its technology is based on a short chain carbohydrate. Its clinical program includes five Phase I clinical trials, five Phase II clinical trials, and two Phase I clinical trials targeting a various cancer, including breast, lung, kidney, head and neck, pancreatic and brain. Its pipeline consists of RAD101, RAD102, RAD104, RAD105, RAD106, and RAD201 among others.

RAD Intrinsic Value
0.218 AUD
Undervaluation 89%
Intrinsic Value
Price
R
Back to Top